Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101
06 Sep 2023 //
BUSINESSWIRE
Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)
25 May 2022 //
BUSINESSWIRE
Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline
07 Feb 2022 //
BUSINESSWIRE
Endeavor BioMedicines Doses First Patient in Phase 2 of Taladegib for IPF
22 Sep 2021 //
BUSINESSWIRE